AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.
|Articles|March 2, 2017
OmniComm, Bio-Optronics to Provide Solutions for Children's Cancer Center
Omnicomm Systems and Bio-Optronics have reached an agreement to integrate OmniComm’s TrialMaster EDC with Bio-Optronics CTMS solution for multiple facilities at a children’s health institution.
Advertisement
Omnicomm Systems and Bio-Optronics have reached an agreement to integrate OmniComm’s TrialMaster EDC with Bio-Optronics CTMS solution for multiple facilities at a children’s health institution seeking to develop cures and treatments for cancer and other diseases.
Read the full release
Advertisement
Related to this article
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
2
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
Start Study Budgets Sooner With AI-Enabled Protocol Translation
5